Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.

ABSTRACT:

Background

There is currently no standard of care for the second-line treatment of advanced pancreatic cancer. The aim of this analysis was to compare the different therapeutic approaches in this setting.

Methods

We carried out a systematic analysis of second-line studies in advanced pancreatic cancer that have progressed on or following gemcitabine and published or presented from 2000 to 2012.

Results

Forty-four clinical trials (t) were identified; of which 34 met the inclusion criteria treating an aggregate total of 1503 patients (n). Patients who received treatments (t: 33; n: 1269) had a median overall survival (OS) of 6 months compared with 2.8 months for patients who received best supportive care only (t: 2; n: 234) (P = 0.013). The gemcitabine and platinum-base

SUBMITTER: Rahma OE 

PROVIDER: S-EPMC3718508 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature